Novonesis stock (DK0060336014): integration progress and Q1 results in focus

Novonesis has reported its first full quarter of combined results after the merger of Novozymes and Chr. Hansen, giving investors new insight into the enlarged biosolutions group’s growth profile and synergy plans.

Novonesis, the biosolutions company formed from the merger of Novozymes and Chr. Hansen, has published its first full set of quarterly figures as a combined group and outlined integration progress, giving investors fresh insight into the enlarged business model and synergy potential, according to a company Q1 2025 trading update released on April 24, 2025 Novonesis investor materials as of 04/24/2025.

In the same update, management commented on organic growth trends across key biosolutions segments and reiterated medium-term targets, while also detailing expected cost synergies from the merger, according to the April 24, 2025 communication and accompanying presentation for investors Novonesis reports and presentations as of 04/24/2025.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novonesis (formed from Novozymes and Chr. Hansen)
• Sector/industry: Biosolutions, industrial biotechnology, ingredients
• Headquarters/country: Denmark
• Core markets: Food and beverages, household care, agriculture, bioenergy and industrial applications
• Key revenue drivers: Enzymes, microbial solutions and specialty ingredients sold to global manufacturers
• Home exchange/listing venue: Nasdaq Copenhagen (Novonesis A/S)
• Trading currency: Danish krone (DKK)

Novonesis: core business model

Novonesis positions itself as a global biosolutions specialist, combining enzyme and microbial technology platforms inherited from Novozymes and Chr. Hansen to serve a broad range of end-markets. The company’s solutions are used by industrial and consumer-goods manufacturers to improve efficiency, reduce resource consumption and enhance product performance, according to corporate descriptions in its investor material published in 2025 Novonesis company overview as of 2025.

The core of the business model is research-driven innovation, with Novonesis investing in biotechnology and fermentation capabilities to create value-added ingredients. These are typically sold on a business-to-business basis, embedded in customers’ formulations rather than marketed directly to end-consumers. The company emphasizes recurring revenue from long-term customer relationships and applications that become integral to clients’ production processes, according to its strategic presentations shared with investors in 2024 and 2025 Novonesis strategy materials as of 2025.

From an operational perspective, Novonesis runs large-scale production facilities for fermentation and downstream processing, supported by application labs and technical service teams. This infrastructure allows it to tailor solutions to specific customer needs, for example designing enzymes optimized for particular detergents or food processes. The merger has broadened the portfolio and customer access, which management argues supports cross-selling and bundled solutions across several industries, as discussed in merger-related documents released in 2024 and early 2025 Novonesis merger information as of 2025.

Main revenue and product drivers for Novonesis

Novonesis generates revenue across a diversified set of applications, with food and beverage ingredients, household care, agriculture, bioenergy and industrial biosolutions all contributing. The company has indicated in its post-merger materials that food and health-related products represent a significant portion of sales, reflecting the legacy strengths of Chr. Hansen, while household care and technical industries draw more heavily on heritage Novozymes capabilities, according to a 2025 investor presentation outlining segment exposure Novonesis reports and presentations as of 2025.

Within food and beverage, Novonesis provides cultures, enzymes and specialty ingredients that can support taste, texture, shelf life and nutritional profiles. In household care, enzymes enable stain removal at lower temperatures, supporting energy savings for consumers. In agriculture, biological solutions aim to improve crop yields and soil health. These applications typically rely on long-running customer partnerships, with Novonesis supplying tailored solutions that are incorporated into branded products sold worldwide, according to business descriptions in its 2024–2025 corporate publications Novonesis solutions overview as of 2025.

From a financial perspective, management has highlighted organic growth and margin resilience as key metrics following the merger. In its Q1 2025 release, the company reported growth indicators for the combined entity and reiterated medium-term ambitions for organic revenue expansion and profitability, while also detailing expected annual cost synergies from integrating overlapping functions and optimizing the manufacturing footprint, according to the April 24, 2025 trading update and presentation Novonesis Q1 2025 materials as of 04/24/2025.

Conclusion

Novonesis is emerging from the integration of Novozymes and Chr. Hansen as a sizeable player in industrial biotechnology and biosolutions, with a broad portfolio spanning food, household care, agriculture and industrial applications. The first full quarter of combined reporting in Q1 2025 provided investors with more clarity on organic growth trends, margin ambitions and synergy plans, while reinforcing management’s focus on innovation-led, recurring B2B revenue. For US investors following global ingredients and sustainability-oriented themes, the stock listed in Copenhagen offers indirect exposure to end-markets worldwide, although the usual integration, competition and macroeconomic factors remain relevant considerations when monitoring the company’s progress.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.